Advertisement
BMEA vs BSEM
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BMEA is a StrongBuy and BSEM is a Buy.
BMEA in upward trend: price expected to rise as it breaks its lower Bollinger Band on October 14, 2026
BMEA may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 27 of 31 cases where BMEA's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 87%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator shows that the ticker has stayed in the oversold zone for 6 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 6 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +4.18% 3-day Advance, the price is estimated to grow further. Considering data from situations where BMEA advanced for three days, in 231 of 272 cases, the price rose further within the following month. The odds of a continued upward trend are 85%.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 14, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on BMEA as a result. In 68 of 72 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.
BMEA moved below its 50-day moving average on September 23, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for BMEA crossed bearishly below the 50-day moving average on October 01, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 9 of 10 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where BMEA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for BMEA entered a downward trend on October 22, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 8 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 49 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.584) is normal, around the industry mean (2.973). P/E Ratio (-3.334) is within average values for comparable stocks, (-1.705). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (128.121) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (438.009).
The Tickeron Price Growth Rating for this company is 95 (best 1 - 100 worst), indicating slightly worse than average price growth. BMEA’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BMEA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
BSEM | ||
|---|---|---|
OUTLOOK RATING 1..100 | 73 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 34 Fair valued | |
PROFIT vs RISK RATING 1..100 | 97 | |
SMR RATING 1..100 | 100 | |
PRICE GROWTH RATING 1..100 | 96 | |
P/E GROWTH RATING 1..100 | 98 | |
SEASONALITY SCORE 1..100 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
| BMEA | |
|---|---|
| RSI ODDS (%) | 2 days ago 82% |
| Stochastic ODDS (%) | 2 days ago 85% |
| Momentum ODDS (%) | 2 days ago 90% |
| MACD ODDS (%) | N/A |
| TrendWeek ODDS (%) | 2 days ago 90% |
| TrendMonth ODDS (%) | 2 days ago 89% |
| Advances ODDS (%) | 8 days ago 85% |
| Declines ODDS (%) | 2 days ago 90% |
| BollingerBands ODDS (%) | 2 days ago 87% |
| Aroon ODDS (%) | 2 days ago 87% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
BMEA’s FA Score shows that 1 FA rating(s) are green while BSEM’s FA Score has 0 green FA rating(s).
- BMEA’s FA Score: 1 green, 4 red.
- BSEM’s FA Score: 0 green, 5 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
BMEA’s TA Score shows that 4 TA indicator(s) are bullish.
- BMEA’s TA Score: 4 bullish, 5 bearish.
Price Growth
BMEA (@Biotechnology) experienced а -30.06% price change this week, while BSEM (@Biotechnology) price change was -18.63% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was +1.28%. For the same industry, the average monthly price growth was -16.27%, and the average quarterly price growth was -16.72%.
Reported Earning Dates
BMEA is expected to report earnings on Nov 03, 2026.
BSEM is expected to report earnings on Nov 12, 2026.
Industries' Descriptions
@Biotechnology (+1.28% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
BMEA and
Correlation & Price change
A.I.dvisor indicates that over the last year, BMEA has been loosely correlated with PROK. These tickers have moved in lockstep 40% of the time. This A.I.-generated data suggests there is some statistical probability that if BMEA jumps, then PROK could also see price increases.
| Ticker / NAME | Correlation To BMEA | 1D Price Change % | ||
|---|---|---|---|---|
| BMEA | 100% | -15.23% | ||
| PROK - BMEA | 40% Loosely correlated | -0.69% | ||
| VYGR - BMEA | 39% Loosely correlated | -7.92% | ||
| CAI - BMEA | 38% Loosely correlated | -1.98% | ||
| EDIT - BMEA | 35% Loosely correlated | -0.80% | ||
| MGX - BMEA | 34% Loosely correlated | -1.52% | ||
More | ||||
BSEM and
Correlation & Price change
A.I.dvisor tells us that BSEM and EYPT have been poorly correlated (+24% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that BSEM and EYPT's prices will move in lockstep.
| Ticker / NAME | Correlation To BSEM | 1D Price Change % | ||
|---|---|---|---|---|
| BSEM | 100% | -1.19% | ||
| EYPT - BSEM | 24% Poorly correlated | -0.44% | ||
| SER - BSEM | 24% Poorly correlated | -0.56% | ||
| ATOS - BSEM | 22% Poorly correlated | +7.51% | ||
| NKTX - BSEM | 21% Poorly correlated | -0.57% | ||
| BMEA - BSEM | 21% Poorly correlated | -15.23% | ||
More | ||||